The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The study was conducted in patients with mild to moderate COVID-19
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Subscribe To Our Newsletter & Stay Updated
